IP Library › Granted Patent US 12,247,053
Granted Patent B2
US 12,247,053 · App. 17/288,133 · Granted Mar 11, 2025

Peptides for inducing heterosubtypic influenza T cell responses

Inventors: Daniel F. Hoft (St. Louis, MO); Christopher S. Eickhoff (St. Louis, MO); Annie De Groot (Providence, RI)
Assignees: Saint Louis University; EpiVax, Inc.
C07K14/11A61K9/19A61K39/145A61K39/39A61K2039/5154
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,247,053
App. No.
17/288,133
Granted
Mar 11, 2025
Kind
B2
Abstract

The present invention provides compositions and methods for generation of an anti-influenza immune response. In particular, conserved T cell epitopes within matrix protein and nucleoprotein components of influenza virus have been identified and further screened for those structures that will bind either or both of HLA I and II molecules. Methods for vaccinating subjects with formulations of such peptides for the treatment or prevention of influenza infection also are described.

Claims (4)

1. A peptide comprising the sequence of SEQ ID NO: 57 or 58.

2. The peptide of claim 1 , wherein said peptide is lyophilized.

3. A nucleic acid encoding the peptide of claim 1 .

4. A method of inducing an immune response in a subject, the method comprising administering to the subject the nucleic acid of claim 3 .

Assignments (4)
SECURITY INTEREST Recorded Jun 30, 2026
From: EPIVAX, INC.; EPV INTERMEDIATE HOLDINGS, LLC
To: FIFTH THIRD BANK, N.A.
Reel/Frame 075141/0047 →
SECURITY INTEREST Recorded Mar 31, 2026
From: EPIVAX, INC.
To: ESCALATE CAPITAL V, LP
Reel/Frame 074239/0943 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2021
From: HOFT, DANIEL F.; EICKHOFF, CHRISTOPHER S.
To: SAINT LOUIS UNIVERSITY
Reel/Frame 057722/0020 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2021
From: DE GROOT, ANNIE
To: EPIVAX, INC.
Reel/Frame 057722/0067 →
Continuity (2)
Provisional Application 62751218 · Oct 26, 2018
Related Publication 20210380644A1 · Dec 9, 2021
References Cited (36)
US 5591430A · Townsend et al. · 1997 [cited by applicant]
US 9265822B2 · Hoft · 2016 [cited by applicant]
US 20020032162A1 · Content et al. · 2002 [cited by applicant]
US 20020147167A1 · Armstrong et al. · 2002 [cited by applicant]
US 20070025968A1 · Van Der Burg et al. · 2007 [cited by applicant]
US 20080032921A1 · Alexander et al. · 2008 [cited by applicant]
US 20100068224A1 · Crea et al. · 2010 [cited by applicant]
US 20110236967A1 · Wollan et al. · 2011 [cited by applicant]
US 20120121628A1 · Leng et al. · 2012 [cited by applicant]
WO WO1994020127 · 1994 [cited by applicant]
WO WO1996010631 · 1996 [cited by applicant]
WO WO1998033888 · 1998 [cited by applicant]
WO WO1999045954 · 1999 [cited by applicant]
WO WO2006124408 · 2006 [cited by applicant]
WO WO2008039267 · 2008 [cited by applicant]
WO WO2008044032 · 2008 [cited by applicant]
Appalla et al. (Accession No. GenBank AGU93020.1, 2013). [cited by examiner]
Eickhoff et al. (Vaccine, Aug. 2019, p. 5371-5381). [cited by examiner]
Assarsson et al. (Journal of Virology 2008, p. 12241-12251). [cited by examiner]
Mils set al. (The Journal of Clinical Investigation, Apr. 2018, vol. 128, p. 1569-1580). [cited by examiner]
Tan et al. (PLoS ONE, Jan. 2010, vol. 5, p. 1-11). [cited by examiner]
Alexander et al., “Universal influenza DNA vaccine encoding conserved CD4 [cited by applicant]
De Groot et al., “Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-2009 conventional influenza vaccine”, [cited by applicant]
De Groot et al., “iVAX: A Sophisticated Suite of Online Vaccine Design Tools”, [cited by applicant]
De Groot et al., “Immune camouflage: relevance to vaccines and human immunology”, [cited by applicant]
Eickhoff et al., “Highly conserved influenza T cell epitopes induce broadly protective immunity”, [cited by applicant]
Heiny, et al., Evolutionarily Conserved Protein Sequences of Influenza A Viruses, Avian an dHuman as Vaccine Targets, [cited by applicant]
Hoft, et al., “Live and Inactivated Influenza Vaccines Induce Similar Humoral Responses, but Only Live Vaccines Induce Diverse T-Cell Responses in Young Children”, [cited by applicant]
Ichihashi et al., “Cross-protective peptide vaccine against influenza A viruses developed in HLA-A*2402 human immunity model”, [cited by applicant]
Invitation to Pay Additional Fees for PCT/US2019/057998 dated Jan. 7, 2020, 2 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2019/057998 dated Mar. 9, 2020, 13 pages. [cited by applicant]
Liu et al., “H7N9 T-cell epitopes that mimic human sequences are less immunogenic and may induce Treg-mediated tolerance”, [cited by applicant]
McMurry et al., “A call to cellular & humoral arms: Enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A”, [cited by applicant]
Moise et al., “Universal H1N1 influenza vaccine development: identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011”, [cited by applicant]
Moise et al., “Immunization with cross-conserved H1N1 influenza CD4 [cited by applicant]
Moise et al., “iVAX: An integrated toolkit for the selection and optimization of antigens and the design of epitope-driven vaccines”, [cited by applicant]